Why the study?
Does semaglutide reduce the incidence of atrial fibrillation in individuals at high cardiovascular risk?
Does semaglutide reduce the incidence of atrial fibrillation in individuals at high cardiovascular risk?
Semaglutide reduces the incidence of atrial fibrillation by 42% in high cardiovascular risk patients, regardless of administration route, diabetes status, or BMI.
Answers are grounded in this paper and cite their sources.
Supports considering semaglutide to lower AF risk in high-CV-risk patients; extends GLP-1 RA benefits to arrhythmia prevention.
Semaglutide significantly reduces the occurrence of incident AF by 42% as compared to placebo in individuals at high CV risk, mainly affected by type 2 diabetes mellitus. This effect appears to be consistent independently of the route of administration of the drug (oral or subcutaneous), the presence of underlying diabetes and BMI.
No takes yet. Share an insight, caveat, or question.
Saglietto et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: